SCHEMBL26879300

SCHEMBL26879300

CC[C@H]1OC[C@@H](N2C(=O)CCC2=O)[C@@H](OCc2ccccc2)[C@H]1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 4/20 0.39
▸ PSEN2 P49810 4/20 0.39
▸ APH1B Q8WW43 4/20 0.39
▸ NCSTN Q92542 4/20 0.39
▸ APH1A Q96BI3 4/20 0.39
▸ PSENEN Q9NZ42 4/20 0.39
▸ CYP2C19 P33261 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ SLC6A2 P23975 1/20 0.37
▸ CYP1A2 P05177 1/20 0.35
▸ BCHE P06276 3/20 0.35
▸ CTSV O60911 1/20 0.35
▸ CTSL P07711 1/20 0.35
▸ CTSB P07858 1/20 0.35
▸ CTSS P25774 1/20 0.35
▸ CTSK P43235 1/20 0.35
▸ CTSC P53634 1/20 0.35
▸ CTSF Q9UBX1 1/20 0.35
▸ PDPK1 O15530 1/20 0.33
▸ MTOR P42345 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26879302 0.89 MAPT (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL26879312 0.88 GRM5 (0.35) CYP2C19MAPTSLC6A2CYP1A2BCHE
SCHEMBL26879340 0.87 MAPT (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL26879303 0.86 GSK3A (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL26879331 0.84 BCHE (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL26879321 0.83 SLC6A2 (0.37) CYP2C19MAPTSLC6A2BCHECTSL
SCHEMBL26879283 0.81 NAAA (0.38) CYP2C19MAPTSLC6A2CYP1A2BCHE
SCHEMBL26900837 0.81 BCHE (0.43) SLC6A2BCHEACHE
SCHEMBL26900838 0.81 BCHE (0.43) SLC6A2BCHEACHE
SCHEMBL26879276 0.80 KMT2A (0.36) SLC6A2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A PSEN1 2696/4885PSEN2 2262/4885APH1B 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback